Johns Hopkins surgeon Marty Makary has been critical of the FDA, especially during the Covid-19 pandemic, for not authorizing innovative products quickly, not emphasizing recommendations from expert panels, and lacking active monitoring of vaccine adverse events. He has been tapped by President-elect Trump to lead the FDA, and his potential changes to the agency include improving authorization processes and increasing monitoring of adverse events. Makary’s views on these issues highlight his potential reform agenda for the FDA if confirmed by the Senate in 2025.
Source link
Seven criticisms of FDA Covid policies offer hints about Makary’s priorities
